^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-07224826

    i
    Associations
    News

    Trials

    Company:
    Pfizer
    Drug class:
    CDK4 inhibitor, CDK6 inhibitor, CDK2 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (NCT05905341)
    Phase 1
    Pfizer
    Withdrawn
    Last update posted :
    11/08/2023
    Initiation :
    01/15/2024
    Primary completion :
    04/14/2026
    Completion :
    04/13/2028
    HER-2
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • PF-07224826